driven by our ethos, the science of sure, we’re a diverse, dedicated, creative team that develops, markets and services some of the most innovative and accurate diagnostic imaging systems and surgical products on the planet. while we’re focused and passionate about our work, we never forget that what we’re really doing is giving people greater confidence and peace of mind in their diagnosis—enabling healthier lives, everywhere, every day. connect with us at hologic.com, on facebook at facebook.com/hologicjobs, and on twitter @hologic_jobs.
Company profile
Ticker
HOLX
Exchange
Website
CEO
Stephen MacMillan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Acessa Health Inc. • Beijing Hologic Technology Co., Ltd. • Benassar Diagnostica-Equipamientos Medicos Unipessoal, Lda. • BioLucent, LLC • Bioptics, Inc. • Biotheranostics, Inc. • Bolder Surgical Holdings, Inc. • Bolder Surgical, LLC • Cytyc Corporation • Cytyc Prenatal Products Corp. ...
IRS number
42902449
HOLX stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
12 Mar 24
10-Q
2024 Q1
Quarterly report
2 Feb 24
8-K
Results of Operations and Financial Condition
1 Feb 24
DEFA14A
Additional proxy soliciting materials
18 Jan 24
DEF 14A
Definitive proxy
18 Jan 24
8-K
Departure of Directors or Certain Officers
12 Jan 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Departure of Directors or Certain Officers
8 Dec 23
10-K
2023 FY
Annual report
21 Nov 23
8-K
Departure of Directors or Certain Officers
13 Nov 23
Transcripts
HOLX
Earnings call transcript
2024 Q1
1 Feb 24
HOLX
Earnings call transcript
2023 Q4
9 Nov 23
HOLX
Earnings call transcript
2023 Q3
31 Jul 23
HOLX
Earnings call transcript
2023 Q2
1 May 23
HOLX
Earnings call transcript
2023 Q1
1 Feb 23
HOLX
Earnings call transcript
2022 Q4
1 Nov 22
HOLX
Earnings call transcript
2022 Q3
28 Jul 22
HOLX
Earnings call transcript
2022 Q2
28 Apr 22
HOLX
Earnings call transcript
2022 Q1
3 Feb 22
HOLX
Earnings call transcript
2021 Q4
2 Nov 21
Latest ownership filings
4
SCOTT T GARRETT
15 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
4
Charles J Dockendorff
11 Mar 24
4
SALLY CRAWFORD
11 Mar 24
4
Amy McBride Wendell
11 Mar 24
4
Stacey D. Stewart
11 Mar 24
4
Christiana Stamoulis
11 Mar 24
4
Nanaz Mohtashami
11 Mar 24
4
LUDWIG HANTSON
11 Mar 24
4
SCOTT T GARRETT
11 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jul 23 | Apr 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.76 bn | 2.76 bn | 2.76 bn | 2.76 bn | 2.76 bn | 2.76 bn |
Cash burn (monthly) | 3.10 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 18.54 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 2.74 bn | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 883.0 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2023
58.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 558 |
Opened positions | 74 |
Closed positions | 191 |
Increased positions | 193 |
Reduced positions | 223 |
13F shares | Current |
---|---|
Total value | 8.59 tn |
Total shares | 137.45 mm |
Total puts | 177.50 k |
Total calls | 132.80 k |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 27.68 mm | $1.98 tn |
STT State Street | 11.10 mm | $793.39 bn |
Victory Capital Management | 5.06 mm | $361.18 bn |
MCQEF Macquarie | 4.24 mm | $302.73 bn |
Renaissance Technologies | 4.02 mm | $286.94 mm |
T. Rowe Price | 3.54 mm | $253.23 mm |
MS Morgan Stanley | 3.39 mm | $242.38 bn |
Parnassus Investments | 2.90 mm | $206.88 bn |
NTRS Northern Trust | 2.71 mm | $193.51 bn |
Dimensional Fund Advisors | 2.50 mm | $178.73 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Mar 24 | Scott T Garrett | Common Stock | Sell | Dispose S | No | No | 75.5 | 16,441 | 1.24 mm | 48,611 |
14 Mar 24 | Scott T Garrett | Common Stock | Option exercise | Acquire M | No | No | 36.04 | 7,402 | 266.77 k | 65,052 |
14 Mar 24 | Scott T Garrett | Common Stock | Option exercise | Acquire M | No | No | 26.74 | 9,039 | 241.70 k | 57,650 |
14 Mar 24 | Scott T Garrett | NQSO Common Stock | Option exercise | Dispose M | No | No | 36.04 | 7,402 | 266.77 k | 0 |
14 Mar 24 | Scott T Garrett | NQSO Common Stock | Option exercise | Dispose M | No | No | 26.74 | 9,039 | 241.70 k | 0 |
7 Mar 24 | Scott T Garrett | Common Stock | Grant | Acquire A | No | No | 0 | 1,572 | 0.00 | 48,611 |
7 Mar 24 | Scott T Garrett | NQSO Common Stock | Grant | Acquire A | No | No | 76.32 | 4,536 | 346.19 k | 4,536 |
7 Mar 24 | Ludwig Hantson | Common Stock | Grant | Acquire A | No | No | 0 | 1,572 | 0.00 | 11,092 |
7 Mar 24 | Ludwig Hantson | NQSO Common Stock | Grant | Acquire A | No | No | 76.32 | 4,536 | 346.19 k | 4,536 |
7 Mar 24 | Nanaz Mohtashami | Common Stock | Grant | Acquire A | No | No | 0 | 1,572 | 0.00 | 2,317 |
News
Hologic Published Results Suggest Proportion Of Early-Stage HR+ Breast Cancer Survivors May Be Over- Or Undertreated Without Breast Cancer Index Genomic Testing
5 Mar 24
First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks
21 Feb 24
UBS Maintains Neutral on Hologic, Raises Price Target to $79
2 Feb 24
Raymond James Maintains Outperform on Hologic, Raises Price Target to $88
2 Feb 24
Amazon To Rally Over 41%? Here Are 10 Top Analyst Forecasts For Friday
2 Feb 24
Press releases
Newly Published Results Reveal a Significant Proportion of Early-Stage HR+ Breast Cancer Survivors May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing
5 Mar 24
Hologic to Unveil Groundbreaking AI Research at ECR 2024
27 Feb 24
Hologic Announces First and Only FDA-Cleared Digital Cytology System – Genius™ Digital Diagnostics System
1 Feb 24
Hologic Announces Financial Results for First Quarter of Fiscal 2024
1 Feb 24
Women's Health Remains in Crisis Worldwide Even as COVID-19 Pandemic Wanes
16 Jan 24